Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Themis-Medicare"

7 News Found

Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr
News | November 06, 2023

Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr

The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023


Themis Medicare launches Lenzetto for treatment of menopausal symptoms
News | January 04, 2023

Themis Medicare launches Lenzetto for treatment of menopausal symptoms

It ensures sufficient serum estradiol levels to alleviate menopausal symptoms


Themis Medicare revenue down 15.26%; Profit down 7.76%
News | November 09, 2022

Themis Medicare revenue down 15.26%; Profit down 7.76%

For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%


Themis Medicare’s VIRALEX effective against viral respiratory infections
News | July 10, 2022

Themis Medicare’s VIRALEX effective against viral respiratory infections

Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.


Themis Medicare gets add on approval for Viralex
Drug Approval | May 18, 2022

Themis Medicare gets add on approval for Viralex

Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties


DCGI approves Themis Medicare's Viralex for Covid-19 treatment
News | March 03, 2022

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections


Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Drug Approval | February 18, 2023

Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing

Themis will market this drug with the brand name REMITHEM.